信迪利单抗联合Nab-PC方案治疗非小细胞肺癌临床价值分析  

Retrospective Analysis of the Clinical Value of the Combination of Sintilimab and Nab-PC Regimen in Non-small Cell Lung Cancer

作　　者：陈辉 许涛 颜海强 Chen Hui;Xu Tao;Yan Haiqiang(Ningde Normal University Affiliated Ningde Hospital,Ningde,Fujian,352210,China)

机构地区：[1]宁德师范学院附属宁德市医院,福建宁德352210

出　　处：《中国初级卫生保健》2024年第12期106-109,共4页Chinese Primary Health Care

摘　　要：目的:探讨信迪利单抗联合白蛋白结合型紫杉醇+卡铂方案(Nab-PC方案)治疗晚期非小细胞肺癌的临床价值。方法:回顾性选取2021年10月—2023年10月宁德师范学院附属宁德市医院收治的105例晚期非小细胞肺癌患者,根据治疗方案不同,将其分为研究组(n=53)和对照组(n=52)。对照组采用Nab-PC方案治疗,研究组在此基础上加用信迪利单抗治疗。比较两组患者总有效率、肿瘤标志物水平、生活质量、生存状况与不良反应。结果:研究组总有效率(67.92%)显著高于对照组(44.23%),差异有统计学意义(P<0.05);研究组无进展生存期、Karnofsky功能状态(KPS)评分、1年生存率、癌症治疗性功能评价量表-肺癌(FACT-L)评分均高于对照组,差异均有统计学意义(P<0.05);研究组糖类抗原125(CA125)、癌胚抗原(CEA)水平均低于对照组,差异均有统计学意义(P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:晚期非小细胞肺癌患者接受信迪利单抗+Nab-PC方案联合治疗,可有效抑制肿瘤增长,改善疾病状况,具有一定的临床应用价值。OBJECTIVE To investigate the efficacy of the combination of sintilimab and albumin bound paclitaxel+carboplatin regimen(Nab-PC regimen)on advanced non-small cell lung cancer(NSCLC),and its effects on tumor markers and immune function in patients.METHODS Totally 105 patients with advanced NSCLC accepted by Ningde Normal University Affiliated Ningde Hospi⁃tal were retrospectively included into a combination group and a control group according to different treatment plans.The control group was treated with Nab-PC regimen,while the combination group was treated with sintilimab.The total effective rate,tumor markers,quality of life,survival status,and toxic side effects of the two groups were compared.RESULTS The total effective rate of the combined group(67.92%)was prominently higher than that of the control group(44.23%)(P<0.05).The progression free surviv⁃al(PFS),Karnofsky Performance Scale(KPS),one-year survival rate,and Functional Assessment of Cancer Therapy-Lung cancer(FACT-L)score of the combined group were prominently higher than those of the control group(P<0.05),while the levels of carbo⁃hydrate antigen 125(CA125),and carcinoembryonic antigen(CEA)were prominently lower than those of the control group(P<0.05).There was no statistically prominent difference in adverse reactions between the two groups(P>0.05).CONCLUSION The combina⁃tion intervention of sintilimab and Rab-PC regimen can effectively inhibit tumor growth and improve disease status in advanced NSCLC patients,and has certain clinical value.

关 键 词：非小细胞肺癌 信迪利单抗 白蛋白结合型紫杉醇 肿瘤标志物 免疫功能 

分 类 号：R735.2[医药卫生—肿瘤]